Free UK shipping on all orders over £50

30 Xativa 12.5mg sublingual wafers
30 Xativa 12.5mg sublingual wafers
30 Xativa 12.5mg sublingual wafers
  • Load image into Gallery viewer, 30 Xativa 12.5mg sublingual wafers
  • Load image into Gallery viewer, 30 Xativa 12.5mg sublingual wafers
  • Load image into Gallery viewer, 30 Xativa 12.5mg sublingual wafers

30 Xativa 12.5mg sublingual wafers

Regular price
£48.00
Sale price
£48.00
Regular price
Sold out
Unit price
per 
Tax included.

LXR are exclusive UK distributors for the award-winning Xativa wafers from the Australian pharmaceutical company iX Biopharma.

Each discreet and easy to use wafer provides a high bioavailability dose of 12.5mg cannabidiol (CBD). They come in a pack sizes of 30 wafers.

We also stock boxes of 60 x 25mg wafers.

Xativa wafers disintegrate within a minute in your mouth and offer fast absorption and a rapid onset of action. They have a proven increased bioavailability of active components. The advantages of the wafers is that they have a predictable absorption combined with a fixed unit dose. 

Xativa wafers are formulated using WaferiX, a patented and award-winning sublingual delivery technology from the Australian pharmaceutical company iX Biopharma.

Each wafer contains a nano-emulsified broad spectrum cannabis extract with:
- 12.5mg CBD and 0mg THC
- 30+ terpenes and other beneficial molecules naturally occurring in cannabis

Xativa CBD wafers are made with a selection of forming agents designed to:
- Minimize time to complete dissolution
- Maximize transfer rate of biological active to the sublingual mucosal membrane
- Minimize swallowing of biological active by the patient 

A pharmacokinetic study* conducted with 24 healthy volunteers in Australia demonstrated that CBD delivered sublingually with WaferiX is:
- Rapidly absorbed
- Dose proportional
- Less variability
- Safe and well tolerated

*Phase 1 study using broad spectrum CBD extract (ECS315) incorporated into WaferiX matrix

Other product information

  • Patented, novel, non-invasive sublingual delivery technology
  • Proprietary freeze-drying manufacturing process
  • WaferiX enables rapid disintegration and release of active CBD for immediate sublingual absorption:
     - highly porous microstructure
     - homogeneous dispersal of active ingredient(s)
     - amorphosity of API retained
     - non-ionic matrix
  • cGMP pharmaceutical grade product
  • Schedule 4 medicine (in Australia)
  • Manufactured in Australia

Xativa wins Australian CBD Product of the Year

Cannabis Industry Awards, Australia